MSD Korea surpassed 500 billion won in sales last year. Keytruda's effect increased 1% year-on-year. Analysts say that it will be able to quickly recover its past sales of 800 billion won before Organon's spin-off. According to MSD audit report, the company recorded 541.9 billion won in sales last year. The figure is up 11.8% from the previous year's 486.8 billion won. During the same period, operating profit shifted from a deficit of 5.8 billion won to a surplus of 58 billion won.

Sales of Keytruda, an immuno-cancer drug of MSD Korea, are evaluated to have been good. Keytruda's sales were not specified, but according to pharmaceutical research firm IQVIA, Keytruda surpassed 200 billion won in annual sales